Abstract Details

Title The potential of Teriflunomide for regional and global brain volume protection in single subject MS patients

Topic Multiple Sclerosis

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 1-008

Objective To determine the potential of Teriflunomide for brain volume protection single subject MS patients.

Background Post-hoc blinded analysis of TEMSO, carried out with SIENA, revealed a significant reduction of annual percentage of volume change. Our pilot study addresses this effect in single MS patients.

Design/Methods

In a prospective, cross-sectional and longitudinal, controlled, not randomized design, 30 consecutive volume data were obtained from high resolution T1 sequences and postprocessed in collaboration with jung diagnostics GmbH by voxel-wise morphometry using SPM 12. The observation period was 24 months. The data analysis was focused on BPV (Brain Parenchyme Volume) and thalamus volume, the region with highest sensitivity for the atrophic process in MS. We grouped the cohort in 3 stages of disease severity: Group 0 (n=10) with no significant BPV or thalamus atrophy; group 1 (n=9) with normal BPV but significant thalamus atrophy and group 2 (n=11) with significant PBV and thalamus atrophy.

Results After 24 months of treatment with Teriflunomide BPV was stable or relatively gained in 63% of the cohort. The positive effect on BPV was highest with 90% in group 0, less with 44% in group 1 and 45% in group 2. The effect on thalamus was more impressive. 73% of the cohort responded with a stable or relatively gained thalamus volume. This effect is equal in group 0 with 75% and group 1 with 71%. With 56% this effect is less impressive in group 2 but still superior compared with BPV. The effect on BPV and thalamus correlates with stability or improvement in SDMT and EDSS. 27% of the cohort did not respond to Teriflunomide in terms of volume stability with a trend to clinical worsening.

Conclusions Our data suggest that Teriflunomide protects brain volume in the majority of our cohort. This effect is best if significant atrophy at baseline does not exist.

Authors/Disclosures
Alaleh Raji, MD PRESENTER	No disclosure on file
Gerhard Winkler	No disclosure on file

��ɫ��

��ɫ��